Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H25F3N4O6 |
Molecular Weight | 534.4844 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]4(COC1=CC=C(C=C1)N2CCC(CC2)OC3=CC=C(OC(F)(F)F)C=C3)CN5C=C(N=C5O4)[N+]([O-])=O
InChI
InChIKey=XDAOLTSRNUSPPH-XMMPIXPASA-N
InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17132069Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24923253
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17132069
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24923253
Delamanid (OPC-67683, Deltyba™) is a nitro-dihydro-imidazooxazoles derivative. It is a mycolic acid biosynthesis inhibitor, an essential component of the cell wall of M. tuberculosis. Delamanid possess highly potent activity against tuberculosis, as shown by its exceptionally low minimum inhibitory concentration range in vitro and highly effective therapeutic activity at low doses in vivo. Delamanid has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis. Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimised background therapy. It is also under review for marketing in Japan for MDR-TB, the first drug application filed in Japan for this indication. Delamanid has been granted orphan drug status in both the EU and Japan.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28092695
Curator's Comment: Delamanid is brain penetrant in rats. No human data available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0071555 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17132069 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | DELTYBA Approved UseDeltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability Launch Date2014 |
Sample Use Guides
The recommended dose for adults is 100 mg twice daily for 24 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28373190
Delamanid exhibited significant bactericidal activity against replicating and dormant bacilli at or above the concentrations of 0.016 and 0.4 mg/L, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
244007
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/07/524
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
||
|
WHO-VATC |
QJ04AK06
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
||
|
WHO-ATC |
J04AK06
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C157406
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
8OOT6M1PC7
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
XX-14
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
9401
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
m11734
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
681492-22-8
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
DTXSID60218326
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
DB11637
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
6480466
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL218650
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
100000127700
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
4819
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
Delamanid
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | |||
|
DELTYBA
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY | APPROVED JULY 2014 | ||
|
SUB33761
Created by
admin on Fri Dec 15 17:10:56 GMT 2023 , Edited by admin on Fri Dec 15 17:10:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY